|
Video: What is a Stock Split?
|
|
Accelerate Diagnostics is an in vitro diagnostics company. Co.'s products include the Accelerate Pheno system, which is its in vitro diagnostic platform and is intended for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including Gram-positive and Gram-negative organisms. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and proprietary single-use test kit. The instrument consists of module(s) connected to a single analysis computer, which allows hospitals to acquire various numbers of modules to address their particular test volume. According to our AXDX split history records, Accelerate Diagnostics has had 1 split. | |
|
Accelerate Diagnostics (AXDX) has 1 split in our AXDX split history database. The split for AXDX took place on July 12, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of AXDX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Accelerate Diagnostics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AXDX split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Accelerate Diagnostics shares, starting with a $10,000 purchase of AXDX, presented on a split-history-adjusted basis factoring in the complete AXDX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/31/2014 |
|
End date: |
03/27/2024 |
|
Start price/share: |
$218.10 |
|
End price/share: |
$1.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.54% |
|
Average Annual Total Return: |
-41.59% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$46.29 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
07/12/2023 | 1 for 10 |
|
|